Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

(Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

from Reuters: Health News http://ift.tt/2Ey0pa2 February 17, 2018 at 06:56AM